

Apollo Life Sciences Holdings (Pty) Limited
BALANCE SHEET AS AT MARCH 31, 2020

	Amount in ZAR	Amount in ZAR
	31-Mar-20	31-Mar-19
A ASSETS		
I Non-current assets		
(a) Property, plant and equipment	-	-
(b) Intangibles assets under development	1,61,988	1,61,988
Total non-current assets	1,61,988	1,61,988
II Current assets		
(a) Inventories	1	334
(b) Financial assets		
(i) Trade receivables	2	952
(ii) Cash and cash equivalents	3	3,230
(c) Other current assets	4	27,548
Total current assets	4,76,496	32,063
TOTAL ASSETS	6,38,484	1,94,051
B EQUITY AND LIABILITIES		
I Equity		
(a) Equity share capital	5	100
(b) Other equity	6	(2,76,200)
Total Equity	(3,87,982)	(2,76,100)
II Liabilities		
1 Current liabilities		
(a) Financial liabilities		
(i) Trade payables	7	2,00,858
(ii) Other financial liabilities	8	2,69,293
(b) Other current liabilities	-	-
Total current liabilities	10,26,467	4,70,151
TOTAL EQUITY AND LIABILITIES	6,38,485	1,94,051

Apollo Life Sciences Holdings (Pty) Limited
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2020

Particulars	Note No.	Amount in ZAR	
		31-Mar-20	31-Mar-19
1 Revenue from operations	9	5,13,714	71,67,235
2 Other Income	10	12	54
3 Total Revenue (1+2)		<u>5,13,727</u>	<u>71,67,288</u>
4 Expenses			
(a) Purchases of stock in trade		5,11,214	71,66,654
(b) Employee benefits expense	11	9,893	-
(c) Finance costs	12	1,070	1,014
(d) Other expenses	13	1,03,432	1,11,696
Total expenses		<u>6,25,609</u>	<u>72,79,364</u>
5 Profit / (Loss) before exceptional items and taxes (3-4)		<u>(1,11,882)</u>	<u>(1,12,076)</u>
6 Exceptional Item		-	-
7 Profit / (Loss) before taxes (5+6)		<u>(1,11,882)</u>	<u>(1,12,076)</u>
8 Tax Expense:			
(1) Current tax		-	-
(2) Deferred tax		-	-
Total tax expenses		-	-
9 Profit / (Loss) for the year after tax		<u>(1,11,882)</u>	<u>(1,12,076)</u>

Apollo Life Sciences Holdings (Pty) Limited
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED MARCH 31, 2020

(A) Equity share capital

Particulars	Amount in ZAR
Balance as at March 31, 2019	100
Changes in equity share capital during the year	-
Balance as at March 31,2020	100

(B) Other equity

Particulars	Money pending allotment	Reserves and Surplus	Items of other comprehensive income	Total
		Retained earnings	Re -measurement of the defined benefit liabilities / (assets)	
Balance as at March 31, 2019		(2,76,200)	-	(2,76,200)
Profit/loss for the year	-	(1,11,882)	-	(1,11,882)
Total comprehensive income	-	(1,11,882)	-	(1,11,882)
Balance as at March 31,2020	-	(3,88,082)	-	(3,88,082)

Apollo Life Sciences Holdings (Pty) Limited
Notes forming part of financial statement

Note

No.

1 Inventories	Amount in ZAR	
Particulars	31-Mar-20	31-Mar-19
Finished goods	-	334
Total	-	334

2 Trade receivables	Amount in ZAR	
Particulars	31-Mar-20	31-Mar-19
Unsecured		
Considered good	70,997	952
Considered doubtful	-	-
	70,997	952
Less: Allowance for doubtful trade receivables	-	-
Total	70,997	952

3 Cash and cash equivalents	Amount in ZAR	
Particulars	31-Mar-20	31-Mar-19
Balances with banks:		
In current accounts	2,01,550	3,230
Total	2,01,550	3,230

4 Other current assets	Amount in ZAR	
Particulars	31-Mar-20	31-Mar-19
Unsecured, considered good		
Loans and advances to suppliers	1,688	14,948
Balances with government authorities:		
-Others	2,02,261	12,600
Total	2,03,949	27,548

5 Share capital	Amount in ZAR	
Particulars	31-Mar-20	31-Mar-19
Issued, subscribed and fully paid-up		
Equity share capital	100	100
Total	100	100

6 Reserves and surplus		Amount in ZAR	
Particulars	31-Mar-20	31-Mar-19	
Surplus in statement of profit and loss			
Opening balance	(2,76,200)	(1,64,124)	
Add: Profit / (Loss) for the year	(1,11,882)	(1,12,076)	
Less: Equity dividend	-	-	
Less: Preference dividend	-	-	
Closing balance	(3,88,082)	(2,76,200)	
Total	(3,88,082)	(2,76,200)	

7 Trade payables		Amount in ZAR	
Particulars	31-Mar-20	31-Mar-19	
Trade payable	3,26,207	2,00,858	
Intra group Trade payable	2,21,468	-	
Total	5,47,675	2,00,858	

8 Other Current financial Liabilities		Amount in ZAR	
Particulars	31-Mar-20	31-Mar-19	
Payable to group entities	-	66,468	
Others	2,02,825	2,02,825	
Povisions	2,75,966	-	
Total	4,78,791	2,69,293	

Apollo Life Sciences Holdings (Pty) Limited
Notes forming part of financial statement

Note

No.

9	Revenue from operations	Amount in ZAR	
		31-Mar-20	31-Mar-19
	Particulars		
	Sale of Product	5,13,714	71,67,235
	Total	5,13,714	71,67,235

10	Other Income	Amount in ZAR	
		31-Mar-20	31-Mar-19
	Particulars		
	Interest Income	12	54
	Total	12	54

11	Employee benefit expenses	Amount in ZAR	
		31-Mar-20	31-Mar-18
	Particulars		
	Salaries and wages	-	63,741
	Superannuation Fund		
	Staff Welfare	9,893	3,161
	Total	9,893	66,902

12	Finance cost	Amount in ZAR	
		31-Mar-20	31-Mar-19
	Particulars		
	Bank charges	1,070	1,014
	Total	1,070	1,014

13	Other Expenses	Amount in ZAR	
		31-Mar-20	31-Mar-19
	Particulars		
	Power and fuel	6,791	6,682
	Rent	45,136	50,781
	Repairs & Maintenance	8,363	634
	Insurance	914	1,250
	Communication expenses	-	7,509
	Advertisement & selling expenses	2,515	-
	Legal & professional fees	32,624	-
	Professional fees	-	36,134
	Miscellaneous expense	7,089	8,706
	Total	1,03,432	1,11,696